Log in

NASDAQ:ADIL - Adial Pharmaceuticals Stock Price, Forecast & News

+0.52 (+30.95 %)
(As of 12/16/2019 06:00 AM ET)
Today's Range
Now: $2.20
50-Day Range
MA: $1.54
52-Week Range
Now: $2.20
Volume351,994 shs
Average Volume52,672 shs
Market Capitalization$22.70 million
P/E RatioN/A
Dividend YieldN/A
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ADIL



Sales & Book Value

Annual SalesN/A
Book Value$0.68 per share


Net Income$-11,630,000.00


Market Cap$22.70 million
Next Earnings Date2/18/2020 (Estimated)
OptionableNot Optionable

Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.

Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Adial Pharmaceuticals.

What price target have analysts set for ADIL?

2 brokerages have issued 12 month price targets for Adial Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Adial Pharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Adial Pharmaceuticals.

What is the consensus analysts' recommendation for Adial Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adial Pharmaceuticals.

Has Adial Pharmaceuticals been receiving favorable news coverage?

Press coverage about ADIL stock has been trending negative on Monday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adial Pharmaceuticals earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Adial Pharmaceuticals.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totalling 44,900 shares, a decrease of 9.7% from the October 31st total of 49,700 shares. Based on an average daily volume of 41,500 shares, the short-interest ratio is currently 1.1 days. Currently, 0.7% of the company's stock are short sold. View Adial Pharmaceuticals' Current Options Chain.

Who are some of Adial Pharmaceuticals' key competitors?

What other stocks do shareholders of Adial Pharmaceuticals own?

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the folowing people:
  • Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)
  • Prof. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 59)
  • Mr. Joseph M. Truluck M.B.A., MBA, CFO & COO (Age 41)
  • Ms. Monika Z. Rogozinska, Chief Devel. Officer
  • Mr. Alex Lugovoy, Head of Strategy

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $2.20.

How big of a company is Adial Pharmaceuticals?

Adial Pharmaceuticals has a market capitalization of $22.70 million. Adial Pharmaceuticals employs 3 workers across the globe.View Additional Information About Adial Pharmaceuticals.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is http://www.adialpharma.com/.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]

MarketBeat Community Rating for Adial Pharmaceuticals (NASDAQ ADIL)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Featured Article: S&P/ASX 200 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel